Sanford Markowitz
Corporate Officer/Principal bei Case Western Reserve University School of Medicine
Profil
Sanford Markowitz was the founder of Rodeo Therapeutics Corp.
which was founded in 2017, where he held the title of Director.
Currently, he is a Professor at Case Western Reserve University School of Medicine since 1988.
Previously, he was a Director at Lucid Diagnostics, Inc. Dr. Markowitz received his undergraduate degree from Harvard University and his doctorate from Yale University.
Aktive Positionen von Sanford Markowitz
| Unternehmen | Position | Beginn |
|---|---|---|
| Case Western Reserve University School of Medicine | Corporate Officer/Principal | 01.01.1988 |
Ehemalige bekannte Positionen von Sanford Markowitz
| Unternehmen | Position | Ende |
|---|---|---|
| LUCID DIAGNOSTICS INC. | Direktor/Vorstandsmitglied | - |
Rodeo Therapeutics Corp.
 Rodeo Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA. | Gründer | - |
Ausbildung von Sanford Markowitz
| Harvard University | Undergraduate Degree |
| Yale University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LUCID DIAGNOSTICS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Rodeo Therapeutics Corp.
Rodeo Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA. | Health Technology |
